Australia markets closed

TC Biopharm (Holdings) Plc (TCBP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.2200+0.1400 (+12.96%)
At close: 04:00PM EST
1.1800 -0.04 (-3.28%)
Pre-market: 08:07AM EST
Full screen
Loading interactive chart…
  • PR Newswire

    TCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK Trial

    TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that the MHRA has officially accepted its proposed amendment to the Company's clinical trial authorisation (CTA). The amendment allows for an increase in dosing size of TCB008 (unmodified expanded gamma delta T cell Lymphocytes) to 12x10^7-23x10^7 gamma delta t-cells.

  • PR Newswire

    TC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit Europe

    TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that CEO, Bryan Kobel and Process Development Manager, Dr. Lauren Bor will be featured "Expert Speakers" at the 7th 7th CAR-TCR Summit Europe, February 27-29th in London, UK.

  • PR Newswire

    TCBP Provides Shareholder Update and Highlights Upcoming Milestones

    TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced a shareholder update with a projected outlook for the current year.